Antiemetic placebo: Reduce adverse drug interactions between chemotherapeutic agents and antiemetic drugs in cancer patients

Medical Hypotheses

Volumn 70, Issue 3, 2008, Pages 551-555

  Zhang, Zhongyi ^a   Wang, Yong ^a   Wang, Yan ^a   Xu, Feng ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b AMRL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BROMOPRIDE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DRONABINOL; FLUOROURACIL; FOLINIC ACID; GRANISETRON; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; METHYLPREDNISOLONE; ONDANSETRON; PAROXETINE; PLACEBO; RIFAMPICIN; SEROTONIN ANTAGONIST;

ANAPHYLAXIS; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; EPIGASTRIC BURNING; EXTRAPYRAMIDAL SYNDROME; FLUSHING; HEADACHE; HUMAN; HYPERSENSITIVITY; NAUSEA AND VOMITING; NONHUMAN; PLACEBO EFFECT; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; NAUSEA; NEOPLASMS; PLACEBO EFFECT; SEROTONIN UPTAKE INHIBITORS; VOMITING;

EID: 38749130464     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.06.029     Document Type: Article

References (55)

1. Conti F., Sergi D., Foggi P., Abbate M.I., and Lopez M. New combination chemotherapy regimens in the primary treatment of operable breast cancer. Clin Ter 158 (2007) 55-75
2. Schwartzberg L.S. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol 5 (2007) 5-12
3. Dharancy S., Podevin P., Aoudjehane L., Batteux F., Rosenberg A.R., Soubrane O., et al. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. Transplantation 83 (2007) 906-911
4. Machover D., Schwarzenberg L., Goldschmidt E., Tourani J.M., Michalski B., Hayat M., et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 66 (1982) 1803-1807
5. Balis F.M. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet 11 (1986) 223-235
6. Scripture C.D., and Figg W.D. Drug interactions in cancer therapy. Nat Rev Cancer 6 (2006) 546-558
7. Kuhlmann J., and Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf 24 (2001) 715-725
8. Blower P., de Wit R., Goodin S., and Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized?. Crit Rev Oncol Hematol 55 (2005) 117-142
9. Finley R.S. Drug interactions in the oncology patient. Semin Oncol Nurs 8 (1992) 95-101
10. van Meerten E., Verweij J., and Schellens J.H. Antineoplastic agents. Drug interactions of clinical significance. Drug Saf 12 (1995) 168-182
11. Minami M., Endo T., Hamaue N., and Hirafuji M. Serotonin and anticancer drug-induced emesis. Yakugaku Zasshi 124 (2004) 491-507
12. Aapro M. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 69 (2005) 97-109
13. Aapro M. Optimising antiemetic therapy: what are the problems and how can they be overcome?. Curr Med Res Opin 21 (2005) 885-897
14. Olver I.N. Update on anti-emetics for chemotherapy-induced emesis. Intern Med J 35 (2005) 478-481
15. Bryson J.C. Clinical safety of ondansetron. Semin Oncol 19 (1992) 26-32
16. Sanwald P., David M., and Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 24 (1996) 602-609
17. Cagnoni P.J., Matthes S., Day T.C., Bearman S.I., Shpall E.J., and Jones R.B. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 24 (1999) 1-4
18. Gilbert C.J., Petros W.P., Vredenburgh J., Hussein A., Ross M., Rubin P., et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 42 (1998) 497-503
19. Chen M., Tanner A., and Gallo-Torres H. Anaphylactoid-anaphylactic reactions associated with ondansetron. Ann Intern Med 119 (1993) 862
20. Kossey J.L., and Kwok K.K. Anaphylactoid reactions associated with ondansetron. Ann Pharmacother 28 (1994) 1029-1030
21. Frigerio C., Buchwalder P.A., and Spertini F. Ondansetron: reasons to be restrictive. Lancet 347 (1996) 1484-1485
22. Ross A.K., and Ferrero-Conover D. Anaphylactoid reaction due to the administration of ondansetron in a pediatric neurosurgical patient. Anesth Analg 87 (1998) 779-780
23. Weiss K.S. Anaphylactic reaction to ondansetron. Arch Intern Med 161 (2001) 2263
24. Dobrow R.B., Coppock M.A., and Hosenpud J.R. Extrapyramidal reaction caused by ondansetron. J Clin Oncol 9 (1991) 1921
25. Halperin J.R., and Murphy B. Extrapyramidal reaction to ondansetron. Cancer 69 (1992) 1275
26. Garcia-del-Muro X., Cardenal F., and Ferrer P. Extrapyramidal reaction associated with ondansetron. Eur J Cancer 29A (1993) 288
27. Tolan M.M., Fuhrman T.M., Tsueda K., and Lippmann S.B. Perioperative extrapyramidal reactions associated with ondansetron. Anesthesiology 90 (1999) 340-341
28. Duncan M.A., Nikolov N.M., and O'Kelly B. Acute chorea due to ondansetron in an obstetric patient. Int J Obstet Anesth 10 (2001) 309-311
29. Sprung J., Choudhry F.M., and Hall B.A. Extrapyramidal reactions to ondansetron: cross-reactivity between ondansetron and prochlorperazine?. Anesth Analg 96 (2003) 1374-1376 table of contents
30. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 4 (2006) 3-8
31. Moerman D.E., and Jonas W.B. Deconstructing the placebo effect and finding the meaning response. Ann Intern Med 136 (2002) 471-476
32. Hrobjartsson A., and Gotzsche P.C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344 (2001) 1594-1602
33. Miller F.G. Is the placebo powerless?. N Engl J Med 345 (2001) 1277 author reply 8-9
34. Spiegel D., Kraemer H., and Carlson R.W. Is the placebo powerless?. N Engl J Med 345 (2001) 1276 author reply 8-9
35. Ader R. Much ado about nothing. Adv Mind Body Med 17 (2001) 293-295 discussion 312-8
36. Greene P.J., Wayne P.M., Kerr C.E., Weiger W.A., Jacobson E., Goldman P., et al. The powerful placebo: doubting the doubters. Adv Mind Body Med 17 (2001) 298-307 discussion 12-8
37. Wickramasekera I. The placebo efficacy study: problems with the definition of the placebo and the mechanisms of placebo efficacy. Adv Mind Body Med 17 (2001) 309-312 discussion 12-8
38. McDonald C.J. Is the placebo powerless?. N Engl J Med 345 (2001) 1276-1277 author reply 8-9
39. Gotzsche P.C. Is there logic in the placebo?. Lancet 344 (1994) 925-926
40. Williams C.J., Bolton A., de Pemberton R., and Whitehouse J.M. Antiemetics for patients treated with antitumor chemotherapy. Cancer Clin Trials 3 (1980) 363-367
41. Schallier D., Van Belle S., De Greve J., and Willekens A. Methylprednisolone as an antiemetic drug. A randomised double blind study. Cancer Chemother Pharmacol 14 (1985) 235-237
42. Chang A.E., Shiling D.J., Stillman R.C., Goldberg N.H., Seipp C.A., Barofsky I., et al. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91 (1979) 819-824
43. Bruera E., Roca E., Cedaro L., Carraro S., and Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69 (1985) 751-754
44. Roila F., Minotti V., Ballatori E., Basurto C., and Tonato M. Evaluation of the antiemetic activity of bromopride in cancer patients treated with i.v. CMF Tumori 71 (1985) 455-458
45. Campora E., Baldini E., Rubagotti A., Chiara S., Bruzzi P., Sertoli M.R., et al. Double-blind randomized trial of lorazepam versus placebo with methylprednisolone for control of emesis due to non-cisplatin containing chemotherapy. J Chemother 2 (1990) 336-339
46. Cubeddu L.X., Hoffman I.S., Fuenmayor N.T., and Finn A.L. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol 8 (1990) 1721-1727
47. Diaz-Rubio E., Martin M., Rosell R., Valerdi J.J., Gonzalez-Larriba J.L., and Barriga J.J. The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide). A randomized, double-blind, cross-over trial. Acta Oncol 30 (1991) 339-342
48. Buser K.S., Joss R.A., Piquet D., Aapro M.S., Cavalli F., Haefliger J.M., et al. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. Ann Oncol 4 (1993) 475-479
49. Cubeddu L.X., Pendergrass K., Ryan T., York M., Burton G., Meshad M., et al. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. Am J Clin Oncol 17 (1994) 137-146
50. Bey P., Wilkinson P.M., Resbeut M., Bourdin S., Le Floch O., Hahne W., et al. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 4 (1996) 378-383
51. Hardy J., Daly S., McQuade B., Albertsson M., Chimontsi-Kypriou V., Stathopoulos P., et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer 10 (2002) 231-236
52. Meiri E., Jhangiani H., Vredenburgh J.J., Barbato L.M., Carter F.J., Yang H.M., et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23 (2007) 533-543
53. Tipton J.M., McDaniel R.W., Barbour L., Johnston M.P., Kayne M., LeRoy P., et al. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 11 (2007) 69-78
54. Bok S. The ethics of giving placebos. Sci Am 231 (1974) 17-23
55. Moerman D.E. The meaning response and the ethics of avoiding placebos. Eval Health Prof 25 (2002) 399-409